DrugPatentWatch Database Preview
Sanofi-aventis Us Company Profile
Email this page to a colleague
» See Plans and PricingUS Patents for Sanofi-aventis Us
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi-aventis Us | ADMELOG | insulin lispro | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | 209196 | 003 | 2018-10-19 | RE43316 | Health Hero Network, Inc. (Palo Alto, CA) | 2017-01-10 | RX | search | |
| Sanofi-aventis Us | ADMELOG | insulin lispro | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | 209196 | 003 | 2018-10-19 | 9,994,615 | Massachusetts Institute of Technology (Cambridge, MA) The Children\'s Medical Center Corporation (Boston, MA) | 2032-02-17 | RX | search | |
| Sanofi-aventis Us | ADMELOG | insulin lispro | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | 209196 | 003 | 2018-10-19 | 9,993,555 | Eli Lilly and Company (Indianapolis, IN) | 2040-03-31 | RX | search | |
| Sanofi-aventis Us | ADMELOG | insulin lispro | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | 209196 | 003 | 2018-10-19 | 9,993,529 | Halozyme, Inc. (San Diego, CA) | 2028-04-28 | RX | search | |
| Sanofi-aventis Us | ADMELOG | insulin lispro | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | 209196 | 003 | 2018-10-19 | 9,982,029 | SANOFI (Paris, FR) | 2035-07-10 | RX | search | |
| Sanofi-aventis Us | ADMELOG | insulin lispro | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | 209196 | 003 | 2018-10-19 | 9,931,380 | 2035-02-19 | RX | search | ||
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
Similar Applicant Names
Companies are sometimes listed under multiple names.
This search can help find similar names.
This search can help find similar names.
